Finance

Lists
Outlook: 70.0% bullish·20.0% bearish
Go to analysis
ELV:NYSE
Elevance Health Inc
425,27 US$
+0,75%
(+3,18) 1D
425,27 US$
0,00% (0,00)
After hours
Closed: 13 ოქტ, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELV...
Open
427,00 US$
High
433,89 US$
Low
420,99 US$
Mkt. cap
91,54 მლრდ.
Avg. vol.
1,20 მლნ.
Volume
1,84 მლნ.
52-wk high
436,24 US$
52-wk low
274,84 US$
Beta
0,70
Shares outstanding
216,87 მლნ.
No. of employees
97 ათ.
Open
427,00 US$
High
433,89 US$
Low
420,99 US$
Mkt. cap
91,54 მლრდ.
Avg. vol.
1,20 მლნ.
Volume
1,84 მლნ.
52-wk high
436,24 US$
52-wk low
274,84 US$
Beta
0,70
Shares outstanding
216,87 მლნ.
No. of employees
97 ათ.
News stories
From web sources and news partners
Profile
Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association. As of 2022, the company had 46.8 million members within its affiliated companies' health plans. Based on its 2021 revenues, the company ranked 20th on the 2022 Fortune 500. In 2023, the company's seat in Forbes Global 2000 rankings was 78. Carelon Global Solutions, Elevance Health's Business Process Outsourcing /Shared Services subsidiary, serves the group's offshore and customer service management. It operates sites in India, Puerto Rico, Philippines, and the United States. Wikipedia
About Elevance Health Inc
CEOგაილ კოზიარა ბუდროხი
Employees96,6 ათ.
Founded1944
Headquartersინდიანაპოლისი, ინდიანა, ამერიკის შეერთებული შტატები
SectorHealth care provider
Analyst ratings
Based on 16 analysts giving stock ratings to ELV in the past 3 months
Buy
Buy
9
Hold
7
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for ELV in the last 3 months.
Highest
Current 425,27 US$
488,00 US$ (+14,75%)
Average
445,07 US$ (+4,66%)
Lowest
393,00 US$ (-7,59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Cassorla
Guggenheim
Buy
Reiterated
460,00 US$
+8,2%
10/12/2026
Andrew Mok CFA
Barclays
Buy
Maintained
469,00 US$
+10,3%
10/07/2026
Ben Hendrix
RBC Capital
Hold
Maintained
424,00 US$
-0,3%
10/07/2026
Lance Wilkes
Bernstein
Buy
Maintained
488,00 US$
+14,8%
10/05/2026
A.J. Rice
UBS
Buy
Maintained
460,00 US$
+8,2%
09/18/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
473,00 US$
+11,2%
09/15/2026
Kevin Fischbeck
Bank of America Securities
Buy
Maintained
480,00 US$
+12,9%
09/11/2026
David Toung
Argus Research
Hold
Maintained
-
-
08/20/2026
Whit Mayo
Leerink Partners
Hold
Reiterated
395,00 US$
-7,1%
07/17/2026
Ryan Langston
TD Cowen
Buy
Reiterated
465,00 US$
+9,3%
07/17/2026
David Windley
Jefferies
Buy
Maintained
450,00 US$
+5,8%
07/16/2026
Scott Fidel
Goldman Sachs
Hold
Maintained
395,00 US$
-7,1%
07/15/2026
Erin Wright
Morgan Stanley
Hold
Reiterated
404,00 US$
-5%
07/17/2026
Michael Ha
Robert W. Baird
Hold
Maintained
393,00 US$
-7,6%
07/16/2026
Amit Daryanani
Evercore ISI
Hold
Maintained
-
-
07/15/2026
David S Macdonald
Truist Financial
Buy
Reiterated
475,00 US$
+11,7%
07/16/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
470,00 US$
+10,5%
07/13/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
450,00 US$
+5,8%
07/07/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
476,00 US$
+11,9%
06/08/2026
George Hill
Deutsche Bank
Buy
Upgraded
498,00 US$
+17,1%
05/20/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Upgraded
360,00 US$
-15,3%
05/19/2026
Next call 8 დღეში
ოთხ, 21 ოქტ, 14:30
Fiscal period
Q3 2026
- / 4,69 US$
Revenue / Est. (USD)
- / 49,16 მლრდ.
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
50,71 მლრდ.
49,75 მლრდ.
50,18 მლრდ.
50,47 მლრდ.
Cost of goods sold
38,14 მლრდ.
38,06 მლრდ.
35,62 მლრდ.
37,02 მლრდ.
Cost of revenue
38,14 მლრდ.
38,06 მლრდ.
35,62 მლრდ.
37,02 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10,65 მლრდ.
10,75 მლრდ.
11,79 მლრდ.
11,04 მლრდ.
Operating expense
10,81 მლრდ.
10,92 მლრდ.
11,90 მლრდ.
11,15 მლრდ.
Total operating expenses
48,95 მლრდ.
48,98 მლრდ.
47,52 მლრდ.
48,17 მლრდ.
Operating income
1,76 მლრდ.
766,00 მლნ.
2,66 მლრდ.
2,30 მლრდ.
Other non operating income
-
-
-
-
EBT including unusual items
1,41 მლრდ.
215,00 მლნ.
2,30 მლრდ.
1,94 მლრდ.
EBT excluding unusual items
1,41 მლრდ.
399,00 მლნ.
2,30 მლრდ.
1,94 მლრდ.
Income tax expense
219,00 მლნ.
-331,00 მლნ.
544,00 მლნ.
483,00 მლნ.
Effective tax rate
15,58%
-153,95%
23,61%
24,94%
Other operating expenses
-
-
-
-
Net income
1,19 მლრდ.
547,00 მლნ.
1,76 მლრდ.
1,46 მლრდ.
Net profit margin
2,34%
1,10%
3,52%
2,90%
Earnings per share
6,03
3,33
12,58
7,45
Interest and investment income
-
-
-
-
Interest expense
-351,00 მლნ.
-367,00 მლნ.
-357,00 მლნ.
-364,00 მლნ.
Net interest expenses
-351,00 მლნ.
-367,00 მლნ.
-357,00 მლნ.
-364,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
2,14 მლრდ.
1,17 მლრდ.
3,02 მლრდ.
2,67 მლრდ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები